Institut Bergonié breast cancer database
Official title: Bergonie Institute Breast Cancer Database
Run by Institut Bergonié · NCT02893761 · Data updated 2026-11-12
This project collects clinical and treatment information from adults treated for breast cancer at Institut Bergonié to see if patient and disease factors relate to survival and outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 30000 (estimated) |
| Sponsor | Institut Bergonié Academic / other |
| Locations | 1 site (Bordeaux) |
| Status | Recruiting |
| Started | January 1990 |
| Main results expected | December 2030 |
| Study ends | December 2050 |
| Registry record updated | September 23, 2025 |
| Trial ID | NCT02893761 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 and over with a diagnosis of breast cancer who received their first treatment at Institut Bergonié are the intended participants.
✕Probably not a fit
People under 18, those without breast cancer, or patients treated entirely at other hospitals would not be included and are unlikely to benefit directly from this database.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The registry compiles clinical, pathological, treatment, and follow-up data on adults diagnosed with breast cancer who received their first treatment at Institut Bergonié, with records dating back to the 1990s and ongoing enrollment. Data are abstracted from medical records and linked to survival outcomes to describe practice patterns and to search for prognostic factors. The database is observational and supports descriptive analyses and hypothesis generation rather than testing a specific therapy. Data are used for institutional quality assessment and research into factors that influence long-term outcomes.
Why it matters
Potential benefit: If successful, the database could help clinicians identify factors linked to better or worse survival and guide improvements in care over time.
How similar studies have gone: Other hospital and population-based breast cancer registries have successfully identified prognostic factors and informed care, so this local database follows a proven approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Breast cancer * Aged 18 years and over * First treatment at Bergonie Institute Exclusion Criteria: \-
Where it's running
-
Institut Bergonié, Comprehensive Cancer Center
Bordeaux, France Recruiting
Study contacts
- Principal investigator: Gaetan Mac Grogan, MD — Institut Bergonié
- Study coordinator: Gaetan Mac Grogan, MD
- Email: g.macgrogan@bordeaux.unicancer.fr
- Phone: + 33 5 56 33 33 33
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Gyrotonic exercise for elders with breast cancer and Behcet disease
We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.
-
PECS II vs SPSIP nerve blocks for pain after mastectomy
This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Compare a new endoscopy-assisted breast-conserving surgery with the usual approach
This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.
-
Different skin care approaches to prevent skin reactions after mastectomy radiation
This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.
-
3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy
This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.